The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 10, pp. 1502-1505. DOI 10.1345/aph.1C474
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jeddy, A. S
Right arrow Articles by Gleason, B. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeddy, A. S
Right arrow Articles by Gleason, B. L

DRUG INFORMATION ROUNDS

OBJECTIF: Réviser les données concernant l'association aspirine et warfarine versus aspirine seule pour la prévention secondaire après infarctus du myocarde.

REVUE DE LITTÉRATURE: Littérature repérée sur MEDLINE (1966 à september 2002). Mots-clés: aspirine, warfarine, prévention secondaire, infarctus du myocarde.

RÉSUMÉ: Malgré l'emploi de faibles doses d'aspirine après infarctus du myocarde, les risques de décès et d'évènements ischémiques restent élevés, rendant impérative la détermination de stratégies pour la prévention secondaire. Il a été évalué les études pertinentes, de grands effectifs et de longue durée, portant sur l'association aspirine–warfarine versus aspirine seule chez des patients après infarctus du myocarde.

CONCLUSIONS: L'aspirine (à des doses quotidiennes de 75 à 325 mg) devrait demeurer le traitement de première ligne pour la prévention secondaire après infarctus du myocarde. L'association d'aspirine (à des doses quotidiennes de 75 à 81 mg) et de warfarine (à intensité modérée: INR de 2.0 à 2.5) est susceptible de procurer un bénéfice supplémentaire, mais devrait être envisagée seulement pour des patients à haut risque d'évènements thromboemboliques.




This article has been cited by other articles:


Home page
 CirculationHome page
U. Stenestrand, J. Lindback, L. Wallentin, and for the RIKS-HIA Registry
Anticoagulation Therapy in Atrial Fibrillation in Combination With Acute Myocardial Infarction Influences Long-Term Outcome: A Prospective Cohort Study From the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA)
Circulation, November 22, 2005; 112(21): 3225 - 3231.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jeddy, A. S
Right arrow Articles by Gleason, B. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeddy, A. S
Right arrow Articles by Gleason, B. L

homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.